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Secondary damageAfter spinal cord injury (SCI), secondary damage caused by oxidative stress, inﬂammation, and ischemia leads to
neurological deterioration. In recent years, therapeutic approaches to trauma have focused on modulating this
secondary cascade. There is increasing evidence that the success of cell-based SCI therapy is duemainly to secreted
factors rather than to cell implantation per se. This study investigated peripheral blood mononuclear cells as a
source of factors for secretome- (MNC-secretome-) based therapy. Speciﬁcally, we investigated whether MNC-
secretomehad therapeutic effects in a rat SCI contusionmodel and its possible underlyingmechanisms. Rats treated
with MNC-secretome showed substantially improved functional recovery, attenuated cavity formation, and re-
duced acute axonal injury compared to control animals. Histological evaluation revealed higher vascular density
in the spinal cords of treated animals. Immunohistochemistry showed that MNC-secretome treatment increased
the recruitment of CD68+ cells with concomitant reduction of oxidative stress as reﬂected by lower expression of
inducible nitric oxide synthase. Notably, MNC-secretome showed angiogenic properties ex vivo in aortic rings
and spinal cord tissue, and experiments showed that the angiogenic potential of MNC-secretomemay be regulated
by CXCL-1 upregulation in vivo. Moreover, systemic application of MNC-secretome activated the ERK1/2 pathway
in the spinal cord. Taken together, these results indicate that factors inMNC-secretome canmitigate the pathophys-
iological processes of secondary damage after SCI and improve functional outcomes in rats.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Injuries to the spinal cord are a devastating form of trauma that
mainly affect young active patients and often result in permanent neu-
rologic deﬁcits, including tetraplegy (Ackery et al., 2004; Cadotte andic Surgery, Christian Doppler
Regeneration, www.applied-
r Gürtel 18–20, A-1090 Vienna,
(H.J. Ankersmit).
. This is an open access article underFehlings, 2011; Filli and Schwab, 2012). Treatment of spinal cord injury
(SCI) remains challenging due to factors such as the limited potential of
axonal regeneration in the human central nervous system and second-
ary mechanisms of injury that can last months after the initial trauma
(Hall and Springer, 2004; Hausmann, 2003; Oyinbo, 2011; Popovich
et al., 1997; Shechter et al., 2009; Tuszynski and Steward, 2012;
Wright et al., 2011). This secondary cascade involves inﬂammation,
neurotoxicity, glial scarring, and thrombocyte activation that, lead to
micro-vascular obstruction (MVO), to injury progression, and to in-
creased neurological impairment (Bowes and Yip, 2014; Hall and
Springer, 2004; Hausmann, 2003; Kwon et al., 2004; Oyinbo, 2011;the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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more, thrombocyte activation directly promotes neuroinﬂammation
and is involved in aggravation of neuronal damage (Joseph et al.,
1991, 1992; Sotnikov et al., 2013; Thornton et al., 2010).
Despite ongoing efforts, a therapy that attenuates secondary damage
after SCI has proven elusive (Cadotte and Fehlings, 2011; Filli and
Schwab, 2012). Cell-based therapies using different types of stem
cells, e.g. bone marrow-derived stem cells (BMSCs), looked promising
in preclinical settings, but the clinical ﬁndings were not convincing
(Filli and Schwab, 2012;Wright et al., 2011). In recent years, researchers
have found that paracrine factors secreted by stem cellsmediate the ob-
served beneﬁcial effects of cell therapy (Gnecchi et al., 2005; Mirotsou
et al., 2011; Teixeira et al., 2013). Cantinieaux et al. reported that treat-
ment with conditioned medium from BMSCs improves motor function
and reduces spinal cord damage after SCI in rats (Cantinieaux et al.,
2013). They showed that the observed therapeutic effectwas duemain-
ly to induction of angiogenesis and modulation of the inﬂammatory re-
sponse of macrophages (Cantinieaux et al., 2013). More recently, a
study reported the ﬁrst use of allogeneic apoptotic cord blood MNCs
in humans; these cells show regenerative potential in critical hind
limb ischemia (Perotti et al., 2013). In contrast to many studies that
usemesenchymal stem cells (MSCs) or other cell types, herewe focused
on conditioned medium from apoptotic peripheral blood mononuclear
cells (PBMCs), which we term MNC-secretome. Previously we showed
that MNC-secretome has regenerative effects in that it attenuates
microvascular obstruction, inhibits platelets, induces vasodilation,
and has immunomodulatory properties (Ankersmit et al., 2009;
Hoetzenecker et al., 2012, 2015; Lichtenauer et al., 2011b; Mildner
et al., 2013; Pavo et al., 2014). More recently, we demonstrated that
MNC-secretome leads to reduction of infarction area in a preclinical
stroke model (Altmann et al., 2014). In addition, the MNC secretome
upregulates pathways associated with cytoprotection in primary neural
crest-derived human cells and induces neuronal sprouting in vitro
(Altmann et al., 2014). Most surprisingly, when applied intraperitoneal-
ly, the humanMNC-secretome causes a huge increase in the expression
of rat brain-derived neurotrophic factor (BDNF) in healthy rodents
(Altmann et al., 2014). Prompted by these encouraging ﬁndings, we be-
came interested in investigating whether MNC-secretome treatment
had similar effects in a rat model of neurotrauma. Accordingly, the
aim of this study was to investigate the effects of MNC-secretome treat-
ment after SCI. For this purpose, we used a well established ratmodel of
spinal cord contusion (Scheff et al., 2003).
Materials & methods
Ethics statement
All animal experiments were approved by the Animal Research Com-
mittee of the Medical University of Vienna (Protocol No. 66.009/0299-II/
3b/2011) and met the Austrian guidelines for the use and care of labora-
tory animals. The local ethics committee at the Medical University of
Vienna (EK2010/034) approved blood donation by healthy volunteers.
All donors provided written informed consent.
Preparation of MNC-secretome
In anticipation of possible future clinical applications, we produced
human apoptotic MNC-secretome according to good manufacturing
practice (GMP) guidelines for all of our experiments (xenogeneic
humanMNCs in a rodent experimentalmodel). Viral clearancewas per-
formed in order to complywith virus safety requirements set by nation-
al regulatory authorities.
Human MNCs were isolated from the whole blood of healthy donors
by density gradient centrifugation. After 60-Gy irradiation, the
cells were cultivated for 24 hwith CellGro® serum-free mediumwithout
phenol red (Cellgenix, Freiburg, Germany) at a concentration of25 × 106 cells/ml under sterile conditions. After centrifugation, the cells
were discarded and the supernatant was collected. The supernatant was
treated with methylene blue (MB) plus light treatment using the
Theraﬂex MB-Plasma system (MacoPharma), the Theraﬂex MB-Plasma
bag system (REF SDV 0001XQ), and an LED-based illumination device
(MacoTronic B2, Maco-Pharma). This process is also used for production
of units of fresh frozen plasma under GMP conditions (Seghatchian
et al., 2011). The light energywasmonitored and reached 180 J/cm2with-
in 20min of illumination time. A pill containing 85mg ofMB is integrated
into the bag system, yielding a concentration range of 0.8–1.2mmol/LMB
per unit. MB and photoproducts are removed by consecutive Blueﬂex ﬁl-
tration steps; notably, a two-step ﬁltration removes over 90% of MB
(Seghatchian et al., 2011). The airwas removed from the plasma units be-
fore illumination. After lyophilization of the viral-inactivated cell culture
supernatant, the lyophilized powder was treated with gamma irradiation
to further reduce the risk of viruses. Gamma irradiation was performed
with a radioactive decay of Cobalt 60 (Gammatron 1500, Mediscan,
Seibersdorf, Austria), leading to the desired sterility of the product. For
this purpose, the MNC-secretome was transferred to metal sterilization
boxes that pass on a meandering path through the irradiation vault
around the emitting center in ﬁve layers. The cobalt unit emits photons
that are almost isotropic. The dose is distributed consistently on the com-
plex path (280positions in 5 layers). The dose rate is recorded by a PMMA
dosimeter and was determined to be 25,000 Gy after 23 h of irradiation.
The lyophilized supernatant of apoptotic MNCs was considered
pathogen-free after this two-step process and was stored at −80 °C
until re-suspension as needed using sterile water (Aqua ad injectabilia,
B Braun, Melsungen, Germany) at a concentration equivalent to
25 × 106 cells/ml. As a control, we processed CellGro® serum-free medi-
um without phenol red in the same fashion as the cell culture superna-
tant. This process of producing human autologous and allogeneic MNCs
was recently approved by the Austrian Health Authority.
Rats and the SCI model
Adult male Sprague Dawley rats (Department of Biomedical Re-
search, Medical University of Vienna, Himberg, Austria) weighing
300–350 g were obtained for our experiments and housed under stan-
dard conditions with alternating 12 h light and dark cycles at the De-
partment of Biomedical Research at the Medical University of Vienna.
Standard lab chow and water was provided ad libitum. In experiments,
the animals were anesthetized with 1.5% isoﬂurane to assure proper in-
traperitoneal (i.p.) application of either medium or MNC-secretome.
Contusion of the spinal cord was performed using a commercially
available spinal cord impactor (Inﬁnite Horizon Impactor, Precision Sys-
tem and Instrumentation, Lexington, KY) as described previously
(Scheff et al., 2003). Brieﬂy, animals were anesthetized with i.p. applica-
tion of xylazine (10 mg/kg) and ketamine (100 mg/kg); anesthesia was
maintained by a continuous ﬂow of 1.5% isoﬂurane. Partial laminectomy
to expose the spinal cord was performed at T11 under sterile conditions.
The vertebral columnwas then stabilizedby clamping the rostral and cau-
dal vertebral bodies with Adson micro forceps (Fine Science Tools,
Heidelberg, Germany). Epidural fat tissue was removed carefully while
leaving the dura intact. The 2.5-mm diameter stainless steel tip was
placed 1 mm above the exposed spinal cord, and a preset force of
150 kDyne was applied with instantaneous retraction of the tip, leading
to a moderate contusion (Scheff et al., 2003). The exposed spinal cord
was examined visually to ensure successful symmetric impact. The surgi-
cal ﬁeldwas irrigatedwith saline, and themuscle and skin openingswere
sutured together in layers. Animals received 10 ml of physiological saline
subcutaneously (s.c.), Carprofen (10 mg/kg) s.c., and Enroﬂoxacin
(10 mg/kg) s.c. for three consecutive days after surgery and were placed
under a heating lamp during recovery. Manual bladder evacuation was
performed twice daily until micturition was present. Animals were ran-
domly divided into two groups, the Medium group and the MNC-
secretome group, and received either 1 ml of processed MNC-secretome
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i.p. 40 min and 24 h after trauma. The treatment timing, frequency, and
dose were determined in preliminary experiments (Altmann et al.,
2014; Hoetzenecker et al., 2012; Lichtenauer et al., 2011b).
For evaluation of cytokine plasma levels 12 rats received a single i.p.
dose of 1 ml containing MNC-secretome (the equivalent of 25 × 106
PBMCs). Plasma was taken from three rats per group sacriﬁced 12 h or
24 h after administration, respectively. Plasma obtained from further
three untreated rats served as negative control (“0 h after treatment”
in Fig. 8). (See Fig. 1.)
Functional assessment
To investigate the possible therapeutic effects of MNC-supernatant,
the overground hind limb locomotion of injured rats was assessed
using the Basso, Beattie, and Bresnahan 21-point open ﬁeld locomotor
rating scale (BBB score) (Basso et al., 1995). The score was determined
before surgery (to exclude preoperative hind limb motor deﬁcits), and
1, 3, 7, 14, 21, and 28 days after surgery. Observers were blinded with
respect to treatment and previous scores. Each hind limb was scored
separately, and themean value of the scores of both limbs for each eval-
uation was used for statistical evaluation.
Preparation of tissue for histological and immunochemical assessment
Animals were anesthetized deeply with xylazine (10mg/kg) i.p. and
ketamine (100mg/kg) i.p. This was followed by puncture of the inferior
vena cava to draw 4ml of blood and by euthanasia, including deep liver
incision and perfusion through the heart with 20 ml of 4% paraformal-
dehyde in PBS. Heparin was added to the blood samples, and the sam-
ples were centrifuged at 3500g for 15 min. Plasma was then removed
and stored at−80 °C. For histological evaluation, the vertebral column,
including the spinal cord, was excised and ﬁxed for 24 h. The spinal cord
was then separated from the vertebral column, and ink marks were ap-
plied 4-mmcranial and 4-mmcaudal from the injury epicenter followed
by dissection of the spinal cord into an average of 10 sections. ForWest-
ern blot analyses, laminectomy was performed on levels T10–T12, and
around 5mm of spinal cord tissue was removed, shock frozen, and
stored at−80 °C until subsequent protein extraction.
Histology and immunohistochemistry
Histological evaluation was performed on parafﬁn-embedded sec-
tions of spinal cords. Hematoxylin & eosin (H&E) and Luxol Fast Blue
staining were performed to assess inﬂammation, myelin breakdown,
and axonal pathology. The following were stained using immunohisto-
chemistry: T cells (CD43/W3/13; Harlan Laboratories, Indianapolis, IN),
β-amyloid precursor protein (βAPP; Chemicon International, CA), mi-
croglia/macrophages (CD68, AbDSerotec, Duesseldorf, Germany), in-
ducible nitric oxide synthase/iNOS (Anti-NOS II, Millipore, MA), andFig. 1. Experimental timeline. Evaluation of motor function was conducted before and on days 1
administered intraperitoneally 40 min and 24 h after SCI. Spinal cords were harvested 3 or 28
Bresnahan score.blood vessels (anti-von Willebrand factor/vWF, Abcam, Cambridge,
UK). For staining, parafﬁn sections were pretreated with a steamer for
60 min. The bound primary antibody was detected with a biotin–avidin
technique as described in detail previously (Kerlero de Rosbo et al.,
1997). To determine axonal pathology using anti-βAPP staining, compa-
rable 0.25 mm2 areas in the lateral column of the injured spinal cord
were deﬁned 4-mm rostral and 4-mm caudal to the injury epicenter.
In this ﬁeld, βAPP-positive ﬁbers were counted using ImageJ software
(Rasband, W.S., ImageJ, U.S. National Institutes of Health; Bethesda,
MD). The area of cavity formation was measured in axial sections 4-
mm cranial and 4-mm caudal to the injury epicenter using ImageJ
planimetry software. The areas of the spinal cord section and cavity for-
mationweremeasured, and their ratio was calculated. Themean values
of the cranial and caudal measurements were then calculated and used
for statistical evaluation. We quantiﬁed CD68 (activated microglia and
macrophages), iNOS, vWF (endothelium), andCD43 (T-cells) as follows.
The dorsal column and the anterolateral white matter were evaluated
separately to distinguish between directly damaged and indirectly dam-
aged spinal cord pathways. The areas andmean number of positive cells
of at least 6 cross sections were counted for each animal and plotted as
cell number/area. Observers blinded to treatment conducted all histo-
logical evaluations and measurements. All measurements were carried
out using ImageJ.
We utilized the diaminobenzidine-enhanced Turnbull blue staining
method (TBB) for the detection of non-heme iron. Ferritin expression
was visualized by immunohistochemistry using rabbit anti-ferritin anti-
body (Sigma, St Louis, MO; dilution: 1:1000, 60 min steaming with
EDTA pH8.5). Slideswere then evaluated using lightmicroscopy. Iron ac-
cumulationwas quantiﬁed by a blinded observerwith the following scor-
ing system: 0 = negative, 1 = low staining intensity, 2 = intermediate
staining intensity, high staining intensity. Microglia and macrophages
were distinguished by morphological appearance.
Aortic ring assay and spinal cord assay
Angiogenic activity was studied using the aortic ring assay based on
the method published by Nicosia and Ottinetti (1990). Ring segments
of rat aorta were sandwiched between two ﬁbrin gels in individual
wells of a 24-well culture plate (Corning, Corning, NY) and overlayed
with M199 medium (Invitrogen, Carlsbad, CA) supplemented with
4 mM L-glutamine (Invitrogen), antibiotic antimycotic solution (100 U
penicillin, 100 μg/ml streptomycin, 250 ng/ml amphotericin B, Sigma,
St. Louis, MO) and 10% FCS (Invitrogen). Fibrin matrices were prepared
as described previously with some modiﬁcations (Ruger et al., 2008). In
brief, human ﬁbrinogen (2 mg/ml, Calbiochem, Darmstadt, Germany)
was dissolved in PBS supplemented with 200 U/ml aprotinin (Gerot
Pharmaceutica, Vienna, Austria) to prevent ﬁbrinolysis. Clotting was ini-
tiated by adding human plasma thrombin (0.6 U/ml, Sigma, St. Louis,
MO). After equilibration, the culture medium was removed and
exchanged with complete M199 without or with the addition of MNC-, 3, 7, 14, 21, and 28 after spinal cord injury (SCI). MNC-secretome or control mediumwas
days after SCI and histological evaluation was performed. BBB score, Basso, Beattie, and
Fig. 2. Improved hind limb motor function after treatment with MNC-secretome. (A) Neurologic evaluation using the Basso, Beattie, and Bresnahan (BBB) scale revealed improved hind limb
motor function at the indicated times after spinal cord injury (SCI) in animals treated with MNC-secretome as shown by the higher BBB scores (mean ± SD; Medium: d7: 7.75 ± 3.52, d14:
11.88±1.76, d21: 13.04±1.94, d28: 13.29±1.84,MNC-secretome: d7: 10.42±1.99, d14: 14.5±1.62, d21: 15.17±1.71, d28: 16.0±1.61;Mediumvs.MNC-secretome: d7: p=0.068, d14:
p b 0.001, d21: p b 0.01, d28: p b 0.01). (B,C) Improvement between day 14 and day 28was not signiﬁcant in the control group (B) (mean± SD ; Day 14: 11.88± 1.76, day 28: 13.29± 1.84,
p=0.07),while in the same timeperiodMNC-secretome treated animals experienced signiﬁcant improvement inmotor function (C) (mean±SD ;Day14: 14.50±1.62, day28: 16.00±1.61,
*p b 0.05). (D, E) Comparison of day 14 (D) and day 28 (E) BBB-scores in both groups (mean± SD; Medium vs. MNC-secretome: Day 14: 11.88± 1.76 vs. 14.50 ± 1.62, ***p b 0.001, day 28:
13.29 ± 1.84 vs. 16.0 ± 1.61 , p b **0,01). n = 12 animals per group.
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secretome + anti-VEGF (300 ng/ml), recombinant rat VEGF (rrVEGF,
100 ng/ml), or rrVEGF + anti-VEGF (100 ng/ml and 300 ng/ml, respec-
tively). The plate was incubated at 37 °C in a 5% CO2/97% humidiﬁed en-
vironment. Culturesweremaintained for 4–7 dayswithmediumchanges
every 2 days. The formation of tubular structures was monitored using a
phase contrast microscope (Olympus IMT-2, Tokyo, Japan) on day 2, day
4, and day 6 using a digital camera (Olympus DP50). Outgrowth length
wasmeasured using ImageJ software (Rasband,W.S., ImageJ, U.S. Nation-
al Institutes of Health; Bethesda, MD).
In order to quantify the cellular outgrowth from the aortic rings, the
ﬁbrin gels were dissolved as described previously (Carrion et al., 2014).
The aortic rings were removed, and the remaining cells were washed
with PBS and counted in a Bürker–Türk counting chamber.
To assess angiogenic capacity in the central nervous system,we used
spinal cord tissue instead of aortic rings. Spinal cord segments (T1–L3)
from healthy rats were embedded in 3D ﬁbrin gels in 24-well culture
plates using the same method as for the rat aortic rings. In some exper-
iments, imaging chambers for high-resolution microscopy (ibidi,Martinsried, Germany) were used for immunoﬂuorescence analyses
and subsequent confocal laser scanning microscopy of the 3D cultures.
For ﬂow cytometry experiments humanMNCswere isolated by den-
sity gradient centrifugation and seeded in 3D ﬁbrin cultures as de-
scribed above. After six days cultures were again dissolved and
processed for ﬂow cytometry experiments.
Flow cytometry
100× 105 cells per 100 μl PBSwere stainedwith 10 μl PE-conjugated
CD14 (clone RMO52), CD163 (clone GHI/61) and FITC-conjugated
CD206 (clone 19.2) or with the appropriate isotype control antibodies
(BD Biosciences) at 4 °C for 15 min. After one washing step, marker ex-
pressionwas analyzed on an FC 500 ﬂow cytometer (Beckman Coulter),
and data were analyzed using the FlowJo software (Tree Star Inc,
Ashland, OR). Living macrophages were gated according to their
forward- and side scatter characteristics and apoptotic or dead cells
were excluded using the Annexin V-FITC/PI apoptosis detection kit
(BD Biosciences).
Fig. 3. Planimetric evaluation of cavity formation. Representative images of Luxol Fast Blue staining of spinal cords from (A) medium treated and (B) MNC-secretome treated animals
28 days after spinal cord injury (SCI). We marked cross sections 4-mm cranial and 4-mm caudal of the macroscopic lesion epicenter and used these for planimetric measurement. We
also measured the cavity formation relative to the total dorsal column for each cross section. Then, the mean of both sections, 4-mm caudal and 4-mm cranial, was calculated for each
rat and used for statistical evaluation and comparison (C; Medium vs. MNC-secretome: 21.81 ± 7.34% vs. 6.1 ± 3.4%, *p b 0.05). n = 4 animals per group.
Fig. 4. Axonal damage was reduced inMNC-secretome treated animals. Immunohistochemical staining for β-amyloid precursor protein showed progressed axonal damage in spinal cord
injury (SCI) animals treated with medium (A) than in animals treated with MNC-secretome (B). Similar to themethod used for planimetric evaluation of lesion volume, cross sections 4-
mm caudal and 4-mm cranial to the lesion epicenter were used for assessment of axonal pathology. Statistical analysis revealed signiﬁcantly less in MNC-secretome treated animals, in-
dicating reduced acute axonal injury (C; Medium vs. MNC-secretome: 16.73 ± 8.67/mm2 vs. 6.5 ± 0.77/mm2, p b 0.05). n = 5 animals per group.
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Fig. 5. Evaluation of angiogenic properties in a rat aortic ring model. (A) Representative phase contrast images of aortic rings cultured for four days in the indicated conditions: Medium,
MNC-secretome,MNC-secretome+anti-VEGF, recombinant VEGF, and recombinant VEGF+anti-VEGF. (B) Graph showing the lengths of vessel sprouts on days 2, 4, and 6 after initiation
of experiments. Aortic rings cultured with MNC-secretome showed the strongest angiogenic response of all groups (2-way ANOVA: MNC-secretome vs. Medium: p b 0.001; MNC-
secretome vs. VEGF: p b 0.001; MNC-secretome vs. MNC-secretome+ anti-VEGF: p b 0.001; MNC-secretome vs. recombinant VEGF+ anti-VEGF: p b 0.001). The lengths of the 3 longest
vessel sprouts were measured, and the mean length was calculated for each aortic ring and used for statistical calculations. (Mean± SEM inmm, Day 2:MNC-secretome: 0.371± 0.023;
Medium: 0.356 ± 0.039; VEGF: 0.328 ± 0.014; MNC-secretome + anti-VEGF: 0.340 ± 0.011; recombinant VEGF + anti-VEGF: 0.000 ± 0.000; Day 4: MNC-secretome: 1.164 ± 0.059;
Medium: 0.703 ± 0.044; VEGF: 0.668 ± 0.052; MNC-secretome + anti-VEGF: 0.963 ± 0.057; recombinant VEGF + anti-VEGF: 0.000 ± 0.000; Day 6: MNC-secretome: 1.579 ± 0.073;
Medium: 0.919 ± 0.109; VEGF: 0.578± 0.027; MNC-secretome+ anti-VEGF: 1.155± 0.106; recombinant VEGF+ anti-VEGF: 0.000 ± 0.000). (C) After ending the experiment and dis-
solving the assaymatrix, therewere signiﬁcantlymore cells in theMNC-secretome group compared to the other groups (MNC-secretome vs.Medium: p b 0.05;MNC-secretome vs. VEGF:
p b 0.01; MNC-secretome vs. MNC-secretome + anti-VEGF: p b 0.05); (Means ± SEM in 104 cells/ml: MNC-secretome: 26.50 ± 1.71; Medium: 4.17 ± 1.75; VEGF: 2.21 ± 1.14; MNC-
secretome + anti-VEGF: 10.96 ± 1.22). *p b 0.05, **p b 0.01. Scale bars, 1 mm. n = 3 per group.
Fig. 6.Angiogenic potential ofMNC-secretome in rat spinal cord tissue. (A) Representative phase contrast image of spinal cord tissue in the 3Dﬁbrinmatrix on day 6 of culturewith control
medium. (B, C) Representative phase contrast images of spinal cord tissue in 3D ﬁbrinmatrix on day 6 of culture withMNC-secretome. (D) Confocal laser scanningmicroscopy 3D-recon-
struction (z-stack) of newly formed vascular sprouts in 3D ﬁbrin matrix on day 6 of culture with MNC-secretome. The vascular structures expressed the endothelial marker RECA-1
(green). Nuclei are stained with DAPI (blue). (E): Graph showing sprout length on day 6 after initiation of 3D culture with either medium or MNC-secretome (Medium: 0.330 ± 0.084,
MNC-secretome: 0.842 ± 0.186, *p b 0.05). Scale bars, as indicated. n = 3 per group.
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Fig. 7.MNC-secretome treatment leads to elevated expression of von Willebrand factor (vWF) in contused spinal cords. (A, B, C, D) Representative images of vWF-staining in the lesion
epicenter (A, B) and in the dorsal column (C, D) 28 days after spinal cord injury (SCI) in animals treated with medium (A, C) or MNC-secretome (B, D). Arrows indicate vasculature ex-
pressing vWF. (E, F) Graphs showing thequantiﬁcation of cells expressing vWF in the lesion epicenter (E) anddorsal column (F) 28days after SCI. (Epicenter:Mediumvs.MNC-secretome:
254.9 ± 78.99/mm2 vs. 541.5 ± 156.5/mm2, p = 0.11; Dorsal column: Medium vs. MNC-secretome: 60.74 ± 8.69/mm2 vs. 131.2 ± 30.84/mm2, *p b 0.05).
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cord 3D cultures
To investigate the vascular phenotype of the cellular outgrowth from
the rat spinal cord segments embedded in the 3D ﬁbrin matrix, whole
cultures were immunostained with RECA-1 (Abcam, Cambridge, UK),
a monoclonal antibody to rat endothelial cells. 3D cultures were ﬁxed
with 4% paraformaldehyde followed by incubation with PBS/0.1 M gly-
cine. After blocking with 5% donkey serum in immunoﬂuorescence (IF)
buffer containing 0.2% Triton X-100, 0.1% BSA, and 0.05% Tween 20 in
PBS, the ﬁbrin gel cultures were incubated with RECA-1 antibodyFig. 8. Upregulation of CXCL-1 in-vivo after intraperitoneal (i.p.) administration of MNC-
secretome. I.p. applicationofMNC-secretome increased the serum levels of CXCL-1 inhealthy
rats 12 h after administration compared to control animals (Medium vs. MNC-secretome:
28.63 ± 9.23 pg/ml vs. 70.5 ± 11.22 pg/ml, *p b 0.05). After 24 h, the difference was not
signiﬁcant (Medium vs. MNC-secretome: 28.63 ± 9.23 pg/ml vs. 49.69 ± 6.65 pg/ml, p =
0.138). The othermeasured cytokines, i.e. IL-10, TNF-α, and IL-1β ,werenot detectable either
12 or 24 h after administration. n = 3 animals per group.(2 μg/ml) for 5 h at RT followed by an extended washing step with IF
buffer. Visualization of the bound antibody was achieved by incubation
with Alexa Fluor 488-labeled donkey anti-mouse antibody (2.5 μg/ml,
Invitrogen). Cultures were washed with IF buffer, the nuclei were
stained with DAPI, and the ﬁbrin gels were stored in PBS at +4 °C
until confocal laser scanning microscopy analysis. The 3D cultures
were evaluated using a LSM 700 confocal laser scanning microscope
(Carl Zeiss, Jena, Germany), and the acquired images were analyzed
with the ZEN image processing and analysis software program (Zeiss).Western blot analysis
To analyze the phosphorylation state of intracellular signalingmole-
cules in the spinal cord, we euthanized healthy rats 2 h after i.p. admin-
istration of either MNC-secretome or medium (control), removed the
T10–T12 segments, and ﬂash froze the segments in liquid nitrogen.
Sample processing and Western blot analysis were carried out as de-
scribed previously (Gschwandtner et al., 2014). Brieﬂy, the samples
were lysed in buffer containing 50mMTris (pH 7.4) and 2% SDS follow-
ed by sonication, centrifugation, protein concentrationmeasurement by
BCA assay (Pierce, Rockford, IL), and denaturation with 0.1 M DL-
dithiothreitol (Sigma-Aldrich). We used 8–18% gradient gels for SDS-
PAGE (GE-Amersham Pharmacia Biotech, Uppsala, Switzerland)
for size fractionation. After electrotransferring the proteins onto
nitrocellulose membranes (Bio-Rad, Hercules, CA) and subsequent
Ponceau S staining, we used the following primary antibodies for
immunodetection: anti-phospho-Erk 1/2 (1:1000), anti-phospho-
CREB (1:1000), anti-phopsho-Hsp27 (Ser15, 1:1000), and anti-
phopsho-Akt (Ser473, 1:1000) (Cell Signalling Technology, Cambridge,
UK); HRP-conjugated goat anti-mouse IgG (1:10,000, Amersham,
Buckinghamshire, UK); and goat anti-rabbit IgG (1:10,000, Thermo
Fisher, Rockford, IL). For detecting reaction products with chemilumi-
nescence, we used the Immun-Star Western C Substrate kit (Bio-Rad).
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culated relative to specimens from untreated healthy rats.
ELISA analysis
Plasma obtained from rats was analyzed with commercially avail-
able ELISA systems (DuoSet, R&DSystems,Minneapolis). These kits spe-
ciﬁcally detect rat cytokines. All assayswere performed according to the
reference manual, and samples were measured in technical duplicates.
We analyzed the following cytokines: CXCL-1/CINC-1, IL-10, IL-1β, and
TNF-α. Optical density values were measured at 450 nm on an ELISA
plate reader (Victor3 Multilabel plate reader, PerkinElmer).
Statistical methods
If not stated otherwise, data are presented asmean±SEM.We com-
pared motor function and data from histological evaluations (area of
cavity formation, APP, CD43, and CD68) between the two groups
using the nonparametric Mann–Whitney U-test. We used the student's
t-test for all other statistical calculations. SPSS software (Version 21,
IBM, NY)was used for all statistical calculations. Graphswere calculated
and plotted with GraphPadPrism 5 (GraphPad, CA). A p-value b 0.05
was deﬁned as the level of signiﬁcance for all experiments.
Results
Treatment with MNC-secretome improves motor function after SCI
To evaluate whether application of MNC-secretome could improve
motor function after SCI, the frequently used BBB-score was utilized
(Basso et al., 1995). Indeed, treatmentwithMNC-secretome led to signif-
icant improvement ofmotor function compared to treatmentwithmedi-
um. The differences became statistically signiﬁcant 14 days after SCI and
remained signiﬁcant until the end of the observation period on day 28
(n = 12; d14: p b 0.001, d21: p b 0.01, d28: p b 0.01; Fig. 2). A BBB
score of 13 on the 21-point scale indicates that coordinated locomotion
of fore and hind limbs can be frequently observed. This represents a im-
portant milestone in regeneration after SCI (Basso et al., 1995). Fourteen
days after trauma, animals in the MNC-secretome treatment group
exceeded this score (mean ± SD: 14.50 ± 1.62), while medium-treated
animals had a score of 11.88 ± 1.76 (mean ± SD) two weeks after SCI.
This difference was highly signiﬁcant with a p-value b 0.001. Contrary
to animals in the control group, we found signiﬁcant improvement of
motor function of MNC-treated animals between day 14 and day 28
post trauma (p b 0.05) (Figs. 2B and C).
Animals treated with MNC-secretome show reduced cavity formation and
axonal damage compared to controls
To determinewhether treatmentwithMNC-secretome resulted in re-
duced secondary damage after SCI, we determined the extent of injury
28 days after trauma. Speciﬁcally, we evaluated the extent of the lesion
using planimetric measurements of the cavity formation relative to the
total dorsal column 4-mm caudal and 4-mm cranial to the epicenter.
This revealed a signiﬁcantly smaller area ofwhitematter cavity formation
28 days post-trauma in animals treated with MNC-secretome (Medium
vs. MNC-secretome: 21.81 ± 7.34% vs. 6.1 ± 3.4%, p b 0.05) (Fig. 3).
To further evaluate the extent of acute axonal injury of motor
pathways, we quantiﬁed βAPP positive axonal spheroids within
the lateral column of the spinal cord. This histological evaluation
showed a signiﬁcant decrease in the lateral column in animals treat-
ed with MNC-secretome compared to control animals (Medium vs.
MNC-secretome: 16.73 ± 8.67/mm2 vs. 6.5 ± 0.77/mm2, p b 0.05)
(Fig. 4).
Finally, we investigated the state of α-motoneurons both 3 and
28 days after SCI (Supp. Figs. 4, 5). CHaT is an enzyme involved in thesynthesis of the neurotransmitter acetylcholine. CHaT staining revealed
pronounced damage around the lesion 3 days after injury in both
groups (Supp. Fig. 4B). Interestingly, on day 28, the spinal cord ap-
peared to be almost totally restored except for small areas of the ventral
roots in both groups (Supp. Figs. 5C, D). We did not detect any differ-
ences between the two groups in terms of CHaT staining at either
time point.
MNC-secretome shows angiogenic properties in aortic rings and in ex vivo
spinal cord tissue
The aortic ringmodel is a commonmodel for studying the angiogen-
ic properties of drugs (Aplin et al., 2008; Nicosia and Ottinetti, 1990). In
this model, we found increased vessel formation and sprouting after in-
cubationwithMNC-secretome compared to the control group (Figs. 5A,
B). Furthermore, after removing the aortic ring and dissolving the ma-
trix, cellularity was signiﬁcantly higher in samples incubated with
MNC-secretome (Fig. 5C). These observed effects were not VEGF-
dependent; however, we noticed destabilization of the newly formed
vessels on day 6 in the groups treated with anti-hVEGF (Fig. 5A and
Suppl. Fig. 1). Recombinant human VEGF served as the positive control
and showed less angiogenic capacity than MNC-secretome. The angio-
genic capacity of rrVEGF was completely inhibited by adding the anti-
VEGF antibody (Figs. 5A, B).
We designed a new assay to investigate whether MNC-secretome
also exhibits these angiogenic properties in spinal cord tissue. Brieﬂy,
instead of aortic rings, we used spinal cord tissue from healthy rats in
the assay. We conﬁrmed the angiogenic effects of MNC-secretome in
spinal cord tissue, similar to our ﬁndings in the aortic ring assay. Most
importantly, endothelial cell outgrowth was positive for RECA-1, an en-
dothelial cell marker (Fig. 6).
Elevated expression of vWF in injured spinal cord following treatment with
MNC-secretome
These ex vivo data suggested the pro-angiogenic properties ofMNC-
secretome. Previous work by our group showed that MNC-secretome
has other effects that can reduce damage after myocardial infarction,
like vasodilation, inhibition of platelet activation, and obviation of
MVO (Hoetzenecker et al., 2012). We therefore examined whether
MNC-secretome might have these effects in an SCI model. We per-
formed immunohistochemical staining against vWF to assess the mi-
crovascular density of the spinal cord (Tseliou et al., 2014; Wei et al.,
2014). The vascular density was signiﬁcantly increased in the entire
dorsal column of the injured spinal cords of animals treated with
MNC-secretome (Medium vs. MNC-secretome: 60.74 ± 8.69/mm2 vs.
131.2 ± 30.84/mm2, p b 0.05) (Figs. 7C, D). There was also increased
vascular density at the lesion site, although it did not reach a statistically
signiﬁcant level (Medium vs. MNC-secretome: 254.9 ± 78.99/mm2 vs.
541.5 ± 156.5/mm2, p = 0.11) (Figs. 7A, B).
MNC-secretome treatment increases CXCL-1 plasma levels in vivo
To further elucidate theMNC-secretomemechanismsof action in vivo,
we investigated whether plasma levels of pro-angiogenic CXCL-1, im-
munemodulatory IL-10, and pro-inﬂammatory TNF-α and IL-1βwere al-
tered in healthy animals treated with MNC-secretome. We found
elevated CXCL-1 plasma levels 12 h after i.p. administration, but the levels
of the other cytokines were unchanged (Fig. 8). However, in the acute
phase of SCI (3 days post-SCI) CXCl-1, TNF-α, and IL-1βplasma levels
showed no differences compared to controls (Supp. Fig. 6).
The immune response after SCI is modulated by MNC-secretome
Monocytes and macrophages are key players in inﬂammatory modu-
lation and in the resolution of inﬂammation after SCI (London et al., 2013;
Fig. 9. Immune response after spinal cord injury ismodulated byMNC-secretome. Immunohistochemical staining of the spinal cord dorsal and anterolateral columns (A, B, G, H) revealed
thatmore cells expressed CD68 in animals treatedwithMNC-secretome 3 days after spinal cord injury (SCI; B, H) compared to animals treatedwith controlmedium (A, G). Despite having
higher levels of CD68+, tissue that was analyzed by immunohistochemistry showed lower expression levels of iNOS after treatment with MNC-secretome (E, K) compared to the spinal
cord dorsal and anterolateral columns of control animals (D, J). I, J, K, L: Graphs show the number of cells expressing CD68 (C, I) and iNOS (F, L) in the dorsal and anterolateral columns of
spinal cord sections (Medium vs. MNC-secretome: C: 12.7± 5.2/mm2 vs. 52.1 ± 11.2/mm2, p b 0.05; F: 2.0± 0.2/mm2 vs. 1.6± 0.1/mm2, p= 0.072; I: 3.5 ± 0.7/mm2 vs. 6.9± 1.7/mm2,
p = 0.097; L: 1.0 ± 0.1/mm2 vs. 0.7 ± 0.1/mm2, p = 0.061).
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secretome treatment modulated the immune response after SCI. Animals
treated withMNC-secretome showed signiﬁcantly increased CD68+ cells
in the dorsal column 3 days after SCI compared to controls (Figs. 9A, B, I).
To assess the extent of nitric oxide radical production, we performed
immunohistological staining of iNOS (London et al., 2013; Shechter
et al., 2009). Despite elevated levels of CD68+ cells, we found decreased
iNOS expression (Figs. 9C, D, J). We observed the same trend in the re-
maining white matter (Figs. 9E, F, G, H, K, L). Furthermore, we detected
a trend towards higher plasma levels of IL-10 on day 3 after SCI in the
MNC-secretome-treated group (Supp. Fig. 2). In contrast, there were sig-
niﬁcantly higher levels of CD68+ cells in the white matter of animals in
the control group 28 days after SCI, while no signiﬁcant differences in
CD68+ cell number were observed within the dorsal column (Fig. 10).
We did not observe any differences in iNOS expression between the
two groups 28 days after trauma (data not shown). Expression of CD43was unaltered by MNC-secretome treatment both on day 3 and on day
28 after trauma (Supp. Fig. 3).Augmented phosphorylation of ERK 1/2 in spinal cord tissue in response to
MNC-secretome treatment
In addition to analyzing the plasma levels of a number of cytokines
involved in inﬂammation, repair, and angiogenesis, we also investigated
the activation of relevant intracellular pathways in the spinal cord after
MNC-secretome treatment in healthy animals without SCI. We found a
signiﬁcant 2.5-fold increase in the phosphorylation of Erk 1/2 in tissue
from these rats compared to tissue from untreated rats (Fig. 11B).
Other pathways that we examined, including the CREB, p38, and
HSP27 pathways, showed no differences in phosphorylation levels be-
tween animals treated with MNC-secretome or with medium (Fig. 11).
Fig. 10. CD68 expression 28 days after spinal cord injury (SCI). Representative images of immunohistological staining of CD68 in spinal cord sections 28 days after SCI. We found signif-
icantly lower expression levels of CD68 in the side and anterior columns of spinal cords after application of MNC-secretome (A; Medium vs. MNC-secretome: 333.8 ± 55.75/mm2 vs.
183.7 ± 47.72/mm2, **p b 0.01). The expression levels of CD68 were slightly higher in the dorsal column in the treatment group, although this difference was not signiﬁcant (B; Medium
vs. MNC-secretome: 467.1 ± 49.4/mm2 vs. 616.9 ± 149.2/mm2, p = 0.21).
Fig. 11.MNC-secretome treatment leads to activation of the Erk-signaling cascade. Spinal cord tissue was obtained from healthy animals 2 h after i.p. treatment with either Medium or
MNC-secretome. (A)Western blot analysis of the phosphorylated signaling factors pErk1/2, pCREB, p-p38, and p-HSP27. (B) Fold increase of pErk1/2 two hours after intraperitoneal treat-
ment with either control medium or MNC-secretome compared to the spinal cord tissue of healthy untreated rats without spinal cord injury.
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Damage to the spinal cord following trauma can lead to permanent
neurological deﬁcits and to ongoing pain. The secondary cascade follow-
ing spinal cord injury aggravates the primary lesion and exacerbates
neurological impairment. This cascade elicits inﬂammation and ische-
mia, with subsequent edema formation, closing the vicious cycle (Filli
and Schwab, 2012; Fleming et al., 2006; Hall and Springer, 2004;
Oyinbo, 2011). Until recently, researchers in the ﬁeld focused mainly
on therapies that targeted mechanisms involved in this secondary
cascade.
In recent years, an increasing number of studies have suggested that
the immune response following SCI—apart from its detrimental
effects—positively inﬂuences the outcome of this type of trauma
(Bowes and Yip, 2014; London et al., 2013; Rapalino et al., 1998;
Shechter et al., 2009). Suggested mechanisms include the induction of
neutrophil apoptosis, the release of neurotropic factors, and axonal re-
growth (Bowes and Yip, 2014; Gordon and Taylor, 2005). Improved un-
derstanding of these mechanismsmade the pursuit of an effective ther-
apy that attenuates secondary damage after SCI evenmore complicated
and there is still a need for a multimodal therapeutic strategy.
Previously published data from our group demonstrated the regen-
erative properties of MNC-secretome (Hoetzenecker et al., 2012;
Lichtenauer et al., 2011b; Mildner et al., 2013). The therapeutic effects
of MNC-secretome include upregulation of anti-apoptotic pathways,
immune system modulation, inhibition of MVO, vasodilation, and inhi-
bition of platelet activation, all of which play major roles in secondary
injury mechanisms (Filli and Schwab, 2012; Fleming et al., 2006; Hall
and Springer, 2004; Hoetzenecker et al., 2012, 2015; Joseph et al.,
1991, 1992; Sotnikov et al., 2013; Thornton et al., 2010). Here we uti-
lized a commonly used spinal cord contusion injury model in rats to in-
vestigate whether the previously published characteristics of MNC-
secretome are also seen in this type of injury.
The data presented here show that MNC-secretome has angiogenic
potential ex vivo (Figs. 5, 6). The observed angiogenic effects were not
dependent on VEGF; however, we observed destabilized vessel struc-
tures on day 6 when anti-VEGF antibody was applied along with
MNC-secretome. The stabilizing and anti-apoptotic effects of VEGF on
endothelial cells have been described previously andmight explain ves-
sel degradation in the absence of VEGF (Folkman and Shing, 1992;
Meeson et al., 1999; Thurston and Gale, 2004). These in vitro data
were corroborated by histological and morphological data evidencing
increased expression of vWF in injured spinal cords after treatment
with MNC-secretome compared to control 28 days after trauma
(Fig. 7). We hypothesize that in addition to possible neo-angiogenesis,
inhibition of MVO and subsequent reduced degradation of obliterated
vessels contribute to this result. These ﬁndings conﬁrmed published
data from our group in which MNC-secretome application led to in-
creased vessel density in a murine wound model (Mildner et al.,
2013). In addition, we found increased plasma levels of pro-
angiogenic rat CXCL-1 after MNC-secretome treatment of rodents
(Fig. 8). CXCL-1, also known as GROα, is known for its role in angiogen-
esis, among other processes (Fuhler et al., 2005; Lichtenauer et al., 2012;
Miyake et al., 2013). Interestingly, some data indicate that overexpres-
sion of CXCL-1 has neuroprotective effects and causes remyelination
(Omari et al., 2009). A previous study reported increased plasma levels
of BDNF, a key modulator in neuronal survival and differentiation, after
MNC-secretome application. This mechanism was very likely involved
in the therapeutic effects observed in the present study (Altmann
et al., 2014; Boyd and Gordon, 2003; Song et al., 2008). Both factors,
i.e. CXCL-1 and BDNF, are reported to act via the Erk 1/2 pathway
(Boyd and Gordon, 2003; Fuhler et al., 2005; Miyake et al., 2013; Song
et al., 2008; Wenjin et al., 2011). I.p. administration of MNC-secretome
resulted in increased phosphorylation of Erk 1/2 in spinal cord tissue
just one hour after application, further suggesting direct activation of
this pathway by factors in the secretome (Fig. 11). Activation of theErk 1/2 pathway was reported previously to be involved in neuropro-
tection (Fu et al., 2014; Toborek et al., 2007).
Because it has both detrimental and beneﬁcial effects, the immune re-
sponse following spinal cord trauma remains a difﬁcult therapeutic tar-
get. Monocyte-derived macrophages are reported to play a central role
in orchestrating the resolution of inﬂammation and the initiation of re-
generative processes, while activation of resident microglia is thought
to aggravate the injury (Rapalino et al., 1998; Shechter et al., 2009). How-
ever, due to their overlapping expression proﬁles, distinguishing be-
tween microglia and monocyte-derived macrophages remains
challenging (London et al., 2013; Popovich and Hickey, 2001).
Consistent with previous studies, we found increased recruitment of
CD68+ cells to the site of injury 3 days after trauma in the MNC-
secretome treated group (Fig. 9) (Lichtenauer et al., 2011b). Upregulation
of iNOS, triggered by pro-inﬂammatory cytokines or iron accumulation
via phagocytosis of erythrocytes, is thought to reﬂect a pro-
inﬂammatory M1 polarization of macrophages. This M1 polarization
wasmainly driven andmaintained by TNF expression and iron accumula-
tion of macrophages and was detrimental to neuronal viability and
neurite growth in-vitro (Bao and Liu, 2002; Hall et al., 2010; Kroner
et al., 2014; Lee et al., 2014; Yune et al., 2003). To evaluate the extent of
M1 macrophage polarization in our study, we evaluated the expression
levels of iNOS (Gehrmann et al., 1995; Han et al., 2013). Immunostaining
revealed thatMNC-secretome treatment led to lower expression levels of
iNOS in injured spinal cords, indicating ameliorated oxidative stress on
day 3 after spinal trauma (Fig. 6). We concluded that increased CD68 ex-
pression plus concomitant reduced iNOS expression in the treatment
group indicates increased recruitment of monocyte-derived macro-
phages. If M1 polarization of macrophages is partially driven by phagocy-
tosis of erythrocytes and subsequent iron accumulation, presumably
comparable amounts of erythrocytes in the SCI lesions phagocytized by
elevated numbers of CD68-positive macrophages in the MNC-
secretome-treated animals could be responsible for decreased iNOS ex-
pression and M1 polarization in individual macrophages. Evaluation of
iron staining revealed lower levels of iron accumulation in animals treat-
ed with MNC-secretome supporting this hypothesis (Supp. Fig. 7).
Conducting ﬂow cytometry, we found that upon incubation with MNC-
secretome human CD14 positive cells up-regulated markers associated
with the immunosuppressive M2-polarization (Supp. Fig. 8) (Biswas
and Mantovani, 2010; Murray and Wynn, 2011). However, this view
has to be substantiated by amore detailed characterization of the possible
change of macrophage phenotypes related toMNC-secretome treatment.
Shechter et al. reported that the expression of IL-10 is essential for the re-
generative potential of monocyte-derived macrophages after SCI
(Shechter et al., 2009). Further supporting our hypothesis, we found a
trend towards higher IL-10 plasma levels in MNC-secretome treated ani-
mals 3 days after spinal cord contusion (Supp. Fig. 2). On post-injury day
28, the number of CD68-positive cellswas signiﬁcantly lower in theMNC-
secretome treatment group compared to control animals, suggesting
more advanced resolution of the inﬂammatory response in animals treat-
ed with MNC-secretome (Fig. 10).
Taken together, these results imply that the combination of effects
observed on vascularization and modulation of inﬂammation lead to
improved motor function in MNC-secretome treated animals after SCI
(Fig. 2). Surprisingly, histological evaluation revealed decreased levels
of βAPP, indicating reduced axonal pathology (Fig. 4); further, lesion
volume was attenuated in the treatment group, indicating that MNC-
secretome reduced secondary damage after SCI (Fig. 3).
CD43 is expressed by all types of T cells, irrespective of their activation
state (Clark and Baum, 2012). Previouswork fromour group showed that
MNC-secretome has inhibitory and immune-suppressive properties and
is protective against experimentally induced T-cell dependent autoim-
mune disease (Hoetzenecker et al., 2015). However, in this study, we
did not observe any differences in CD43 expression between the MNC-
secretome group and theMedium control group (Supp. Fig. 3), indicating
an unaltered total number of T-cells in injured spinal cord after MNC-
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MNC-secretome treatment on the phenotype of T-cells in the setting of
experimental SCI but was not further evaluated in this study.
We extended our ﬁndings by investigating differences in the ChaT
staining in the treatment and control groups 3 and 28 days after trauma
(Supp. Figs. 4, 5).Wehypothesized that functional preservation in treat-
ed animals correlated with less acute axonal injury, as reﬂected by
lower βAPP levels, rather than morphological recovery observable by
day 28 in the ChaT staining.
Multiple previously studies have examined treatment with a single
factor for complex models of disease. A study published by Lutton
et al. reported the beneﬁcial effects of the growth factors PDGF and
VEGF after spinal cord hemisection in rats (Lutton et al., 2012). Interest-
ingly, only the use of both factors together proved efﬁcacious, while ei-
ther PDGF or VEGF alone had deleterious effects that were recently
conﬁrmed in a contusion injury model (Chehrehasa et al., 2014;
Lutton et al., 2012).
Here we present compelling evidence that MNC-secretome can af-
fect multiple biological mechanisms involved in attenuating secondary
damage after SCI. Both PDGF and VEGF are present in MNC-secretome
and might be involved in its observed therapeutic effects (Lichtenauer
et al., 2011a).
Over the years, the focus of the ﬁeld of cell-based therapy hasmoved
away from a “cell-centric” view and towards soluble paracrine factors
that have observed effects in multiple pre- and clinical studies
(Cantinieaux et al., 2013; Quertainmont et al., 2012; Teixeira et al.,
2013; Wright et al., 2011). The ﬁrst publication in the literature that
supported the “paracrine hypothesis” was published in 2005 by
Gnecchi et al. (2005). A recent study described the regenerative and im-
munomodulatory effects of the application of BMSC-conditioned medi-
um in a SCI rat model, ﬁndings that are in accordance with our results
(Cantinieaux et al., 2013).
In contrast to obtaining bone marrow stem cells and their paracrine
factors, the method used to obtain MNC-secretome is simple. In previ-
ous work we showed that MNC-secretome could modulate internal in-
ﬂammatory reactions in experimental stroke, acute myocardial
infarction, and myocarditis (Altmann et al., 2014; Hoetzenecker et al.,
2012; Hoetzenecker et al., 2015; Lichtenauer et al., 2011b).
A recent study compared the expression proﬁles of stem cells and
MNCs (Korf-Klingebiel et al., 2008). The authors found similar cytokine
concentrations in the supernatants of both cell types, with small differ-
ences in 35 of the 174 investigated secreted factors. MNCs have advan-
tages compared to stem cells as “bioreactors” because (a) MNCs are an
underutilized raw material in that currently MNCs are a waste product
of the blood product generation process; (b) the secretome derived
from MNCs shows minimal or no antigenicity owing to the absence of
cellular epitopes; (c) MNC-secretome is easy to produce;
(d) lyophilizing the conditioned medium allows “off the shelf” utiliza-
tion in a clinical setting; (e) the steps involved in MNC-secretome pro-
duction, including viral clearance, can be adapted to the setting of a
GMP production line (which is a mandatory regulatory requirement
for later clinical use in humans).
In an experimental setting, we administered the xenogenic human
MNC-secretome i.p. rather than applying it locally in order to determine
whether systemic application produces the desired effects found previ-
ously in experimental SCI (Abrams et al., 2012; Lee et al., 2014;
Ravikumar et al., 2007). There are two possible explanations for the ef-
ﬁcacy of systemic treatment. First, the breakdown of the blood–brain
barrier after SCI allows penetration of systemic therapies; second, the
systemic inﬂammatory response to trauma is decisive in terms of the
extent of second injury (Abrams et al., 2012; Lee et al., 2014;
Ravikumar et al., 2007).
Our data conﬁrmed that the human-derived MNC-secretome atten-
uates secondary damage after experimental SCI. Currently we have ap-
proval from the Austrian Health Authority (AGES) to produce human
allogeneic MNC secretome according to GMP guidelines, includingmandatory viral clearance methods. This study provides a sound basis
for the use of MNC-secretome in future SCI clinical trials.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.expneurol.2015.03.013.
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